Should you buy Dianthus Therapeutics stock now?
Yes, the technical signal for Dianthus Therapeutics is currently BUY. Dianthus Therapeutics trades at $108.61 as of 8/6/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 4.465 with rising momentum (signal: 4.116); RSI is at 62.8 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $129.75 points to 19.5% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Dianthus Therapeutics stock?
The average analyst price target for Dianthus Therapeutics is $129.75. The current price is $108.61, which gives an upside of 19.5%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $116.78 and $142.73.
Is Dianthus Therapeutics a dividend stock?
No, Dianthus Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Dianthus Therapeutics stock?
Dianthus Therapeutics is rated as a stock with high risk. the annual standard deviation is 66.3%, which classifies the stock as high risk.
Is Dianthus Therapeutics overvalued?
No, Dianthus Therapeutics is considered undervalued based on the analyst price target (19.5% upside). Dianthus Therapeutics has the following valuation ratios: a P/S ratio of 4,517.3, a P/B ratio of 4.9. The analyst price target suggests that the stock is undervalued by 19.5%.
Is Dianthus Therapeutics overbought?
No, Dianthus Therapeutics is not overbought. RSI is at 62.8 (neutral zone). The technical indicators show: RSI is at 62.8 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 4.7% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Dianthus Therapeutics earnings report?
The date of the next earnings report for Dianthus Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Dianthus Therapeutics shorted?
Yes, Dianthus Therapeutics is shorted with 19.4% of the free float sold short. This is a very high level of short selling, which points to considerable bearish sentiment. A positive earnings report or unexpectedly good news can trigger a short squeeze with sharp price gains. Data is updated daily based on official filings with the SEC.
Are insiders buying Dianthus Therapeutics stock?
No, insiders are not buying Dianthus Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 3 sales. On a net basis, 5,993,158 $ worth of shares were sold. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 59,357,363 $ sold. Active sellers include Savitz Ryan, Veness Adam M, Randhawa Simrat and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Dianthus Therapeutics a good stock?
Based on our total score, Dianthus Therapeutics is rated as a mediocre stock with a total score of 40 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 8/100, Quality: 14/100, Momentum: 98/100. In addition: analysts see 19.5% upside to the price target; technical signal: Strong Buy. Whether Dianthus Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Dianthus Therapeutics stock?
The outlook for Dianthus Therapeutics based on current data: the average analyst price target is $129.75 (+19.5%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Dianthus Therapeutics stock rising?
Dianthus Therapeutics is rising right now. The technical indicators show: the price is 4.7% above the 20-day average; MACD is positive with rising momentum (bullish signal); short interest is 19.4% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Dianthus Therapeutics go?
The average analyst price target for Dianthus Therapeutics is $129.75, which corresponds to a potential gain of 19.5% from the current price of $108.61. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Dianthus Therapeutics fall?
We lack enough history to give a specific floor for Dianthus Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Dianthus Therapeutics do?
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclo... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Dianthus Therapeutics as an investment.
Did Dianthus Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Dianthus Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Dianthus Therapeutics making money or losing money?
We have no current profitability data for Dianthus Therapeutics. See the latest report in the earnings history above.
Can Dianthus Therapeutics go bankrupt?
The bankruptcy risk of Dianthus Therapeutics is rated as low. Altman Z2 (a model for assessing financial distress) is 32.32 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 6% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Dianthus Therapeutics have a lot of debt?
No, Dianthus Therapeutics has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 6%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
